Levetiracetam Zentiva (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding stabilizes neuronal membranes and diminishes excessive neuronal firing, thereby lowering the likelihood of seizure initiation and spread throughout the brain.

The appropriate dose of Levetiracetam Zentiva is determined individually by a prescriber based on the patient’s age, weight, renal function, and seizure type. Healthcare professionals tailor the regimen to achieve optimal seizure control while minimizing side effects.

Safety data for levetiracetam in pregnancy and lactation are limited. The prescriber should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women, and discuss alternative options if concerns arise.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It is generally well tolerated, has fewer drug‑enzyme interactions, and can be used as monotherapy or adjunctive therapy depending on the clinical scenario.

Store Levetiracetam Zentiva at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Maintaining these conditions helps preserve the product’s stability and potency throughout its shelf life.

Levetiracetam Zentiva is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with water; patients should follow the exact schedule and dosage prescribed to maintain consistent blood levels.

Serious risks include severe allergic reactions, skin conditions such as Stevens‑Johnson syndrome, blood dyscrasias, and emerging suicidal thoughts or depression. Patients should seek immediate medical attention if they notice rash, swelling, mood changes, or any signs of a severe reaction.

Individuals with known hypersensitivity to levetiracetam or any of its excipients should avoid the product. Patients with severe renal impairment may require alternative therapy or careful dose adjustment, and it should be used only under medical guidance in such cases.